In April of 2021, we provided a three-part series relating to the IP and Competitive Landscape for the mRNA market.
Continue Reading mRNA Patent and Competitive Landscape: 2021 Year in Review and 2022 Outlook
Dan Shores is a partner at Rothwell, Figg and founder of its Boston office. He serves companies operating in dynamic biotech and other markets building patent portfolios, litigating complex patent disputes, negotiating strategic collaborations, and conducting due diligence and landscape investigations. Dan has served companies utilizing the following technologies (without limitation): mRNA; lipid nanoparticles; CAR-T; oligonucleotides; genetically engineered swine organs for xenotransplantation; artificial intelligence for drug discovery; small molecules; biologics, materials science, and numerous other technologies throughout his 20-year career. Dan has a B.S. in engineering with a specialization in materials science from the University of New Hampshire and a J.D. from the Georgetown University Law Center. He is a registered patent attorney licensed to practice before the United States Patent and Trademark Office, and is admitted to practice law in Massachusetts and in the District of Columbia. He is a member of the bars of the Supreme Court of the United States, United States Court of Appeals for the Federal Circuit, and United States District Court for the District of Massachusetts.
In April of 2021, we provided a three-part series relating to the IP and Competitive Landscape for the mRNA market.
Continue Reading mRNA Patent and Competitive Landscape: 2021 Year in Review and 2022 Outlook
Introduction
Universities and certain colleges in the United States (US) spend billions of dollars on research and development (R&D) each…
Continue Reading Three (3) Initial Considerations for Entrepreneurial Faculty, Researchers, Post-Docs, and Graduate Students
Google’s parent company Alphabet announced the launch of a new company this week dedicated to applying deep learning methods to…
Continue Reading Alphabet Dives Further Into AI-Driven Drug Discovery
mRNA pioneer BioNTech announced recently that it is developing an mRNA-based vaccine to attempt to eradicate malaria. Its efforts are…
In Part I of this series providing a summary of the mRNA IP and competitive landscape through one year of…
Continue Reading The mRNA Patent and Competitive Landscape: Pioneers, Litigation Outlook and Big Pharma’s Next Moves (Part III)
In Part I of this three-part series, we focused on three mRNA technology market players: BioNTech, Moderna and CureVac.
Continue Reading The mRNA Patent and Competitive Landscape: Translate BIO; Arcturus; eTheRNA and Other Startups; and LNP Technology (Part II)
Shortly after we posted about Moderna, Inc.’s October 2020 pledge not to enforce its COVID-19-related patents during the pandemic, the…
Continue Reading The mRNA Patent and Competitive Landscape Through One Year of the COVID-19 Pandemic–Part I
Founders of emerging companies must decide early on in their company’s growth cycle whether to require employees to assign their…
Continue Reading IP Assignment Considerations for Emerging Companies
2021 started off well for Dana-Farber Cancer Institute, with the launch of its new venture fund, Binney Street Capital, …
Continue Reading Dana-Farber Launches New Fund to Support Oncology Startups
Hyundai is reportedly in the process of purchasing a large controlling interest in robot innovator Boston Dynamics from SoftBank in
…
Continue Reading Hyundai Buys Majority of Boston Dynamics from SoftBank in $1.1B deal
We use cookies to enhance your user experience. By continuing to use this site you are giving your consent for us to use cookies. For more information, please see our Privacy Policy.